GSK: FDA approves cancer drug Blenrep
(CercleFinance.com) - GlaxoSmithKline announced on Thursday that it has received marketing approval from the US FDA for its Blenrep antibody for the treatment of multiple myeloma.
The US health authority's approval concerns patients with relapsed and refractory multiple myeloma who have already tried at least four other treatments, the pharmaceutical group said.
Although this form of myeloma is currently the second most common form of blood cancer in the US, these patients often have a limited number of treatment options, GSK explains.
The British company points out that the approval of Blenrep is its fifth "major" drug approval since the beginning of the year in its preferred fields of oncology, HIV and chronic kidney disease.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The US health authority's approval concerns patients with relapsed and refractory multiple myeloma who have already tried at least four other treatments, the pharmaceutical group said.
Although this form of myeloma is currently the second most common form of blood cancer in the US, these patients often have a limited number of treatment options, GSK explains.
The British company points out that the approval of Blenrep is its fifth "major" drug approval since the beginning of the year in its preferred fields of oncology, HIV and chronic kidney disease.
Copyright (c) 2020 CercleFinance.com. All rights reserved.